<?xml version='1.0' encoding='utf-8'?>
<document id="23058051"><sentence text="Effect of multidose cilostazol on pharmacokinetic and lipid profile of atorvastatin in male Wistar rats."><entity charOffset="20-30" id="DDI-PubMed.23058051.s1.e0" text="cilostazol" /><entity charOffset="71-83" id="DDI-PubMed.23058051.s1.e1" text="atorvastatin" /><pair ddi="false" e1="DDI-PubMed.23058051.s1.e0" e2="DDI-PubMed.23058051.s1.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s1.e0" e2="DDI-PubMed.23058051.s1.e1" /></sentence><sentence text="Atorvastatin (ATV) and cilostazol (CLZ) are often co-prescribed to treat conditions such as peripheral arterial disease"><entity charOffset="0-12" id="DDI-PubMed.23058051.s2.e0" text="Atorvastatin" /><entity charOffset="14-17" id="DDI-PubMed.23058051.s2.e1" text="ATV" /><entity charOffset="23-33" id="DDI-PubMed.23058051.s2.e2" text="cilostazol" /><entity charOffset="35-38" id="DDI-PubMed.23058051.s2.e3" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e0" e2="DDI-PubMed.23058051.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e0" e2="DDI-PubMed.23058051.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e0" e2="DDI-PubMed.23058051.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e0" e2="DDI-PubMed.23058051.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e1" e2="DDI-PubMed.23058051.s2.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e1" e2="DDI-PubMed.23058051.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e1" e2="DDI-PubMed.23058051.s2.e3" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e2" e2="DDI-PubMed.23058051.s2.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s2.e2" e2="DDI-PubMed.23058051.s2.e3" /></sentence><sentence text=" In the present study, the drug-drug interaction potential of multi-dose CLZ on both pharmacokinetics and the lipid-lowering ability of single-dose ATV is demonstrated"><entity charOffset="148-150" id="DDI-PubMed.23058051.s3.e0" text="ATV" /><entity charOffset="73-75" id="DDI-PubMed.23058051.s3.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s3.e1" e2="DDI-PubMed.23058051.s3.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s3.e1" e2="DDI-PubMed.23058051.s3.e0" /></sentence><sentence text="" /><sentence text="The pharmacokinetic parameters of ATV were determined in Wistar rats after per-oral pre-treatment with CLZ for 7 days in order to assess the interaction potential between ATV and CLZ"><entity charOffset="34-36" id="DDI-PubMed.23058051.s5.e0" text="ATV" /><entity charOffset="171-173" id="DDI-PubMed.23058051.s5.e1" text="ATV" /><entity charOffset="103-105" id="DDI-PubMed.23058051.s5.e2" text="CLZ" /><entity charOffset="179-181" id="DDI-PubMed.23058051.s5.e3" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e0" e2="DDI-PubMed.23058051.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e0" e2="DDI-PubMed.23058051.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e0" e2="DDI-PubMed.23058051.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e0" e2="DDI-PubMed.23058051.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e2" e2="DDI-PubMed.23058051.s5.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e2" e2="DDI-PubMed.23058051.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e2" e2="DDI-PubMed.23058051.s5.e3" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e1" e2="DDI-PubMed.23058051.s5.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s5.e1" e2="DDI-PubMed.23058051.s5.e3" /></sentence><sentence text=" In-vitro metabolic inhibition and everted gut sac studies were conducted to elucidate the mechanism of this interaction" /><sentence text=" Biochemistry analyser was used to estimate lipid profiles in Wistar rats" /><sentence text=" A validated LC-MS/MS method was employed to simultaneously quantify both ATV and CLZ in rat plasma matrix"><entity charOffset="74-76" id="DDI-PubMed.23058051.s8.e0" text="ATV" /><entity charOffset="82-84" id="DDI-PubMed.23058051.s8.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s8.e0" e2="DDI-PubMed.23058051.s8.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s8.e0" e2="DDI-PubMed.23058051.s8.e1" /></sentence><sentence text="" /><sentence text="A statistically significant increase in systemic exposure to ATV after a single dose was observed in CLZ pre-treated rats"><entity charOffset="61-63" id="DDI-PubMed.23058051.s10.e0" text="ATV" /><entity charOffset="101-103" id="DDI-PubMed.23058051.s10.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s10.e0" e2="DDI-PubMed.23058051.s10.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s10.e0" e2="DDI-PubMed.23058051.s10.e1" /></sentence><sentence text=" In-vitro metabolism studies using rat liver microsome (RLM) demonstrated statistically significant inhibition of ATV metabolism when co-incubated with CLZ"><entity charOffset="114-116" id="DDI-PubMed.23058051.s11.e0" text="ATV" /><entity charOffset="152-154" id="DDI-PubMed.23058051.s11.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s11.e0" e2="DDI-PubMed.23058051.s11.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s11.e0" e2="DDI-PubMed.23058051.s11.e1" /></sentence><sentence text=" No change in apparent permeability of ATV was observed in the presence of CLZ"><entity charOffset="39-41" id="DDI-PubMed.23058051.s12.e0" text="ATV" /><entity charOffset="75-77" id="DDI-PubMed.23058051.s12.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s12.e0" e2="DDI-PubMed.23058051.s12.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s12.e0" e2="DDI-PubMed.23058051.s12.e1" /></sentence><sentence text=" The blood lipid profile study after ATV administration indicated a statistically significant decrease in total cholesterol, triglycerides and LDL-cholesterol"><entity charOffset="112-123" id="DDI-PubMed.23058051.s13.e0" text="cholesterol" /><entity charOffset="125-138" id="DDI-PubMed.23058051.s13.e1" text="triglycerides" /><entity charOffset="143-158" id="DDI-PubMed.23058051.s13.e2" text="LDL-cholesterol" /><entity charOffset="37-51" id="DDI-PubMed.23058051.s13.e3" text="ATV" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e3" e2="DDI-PubMed.23058051.s13.e3" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e3" e2="DDI-PubMed.23058051.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e3" e2="DDI-PubMed.23058051.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e3" e2="DDI-PubMed.23058051.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e0" e2="DDI-PubMed.23058051.s13.e0" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e0" e2="DDI-PubMed.23058051.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e0" e2="DDI-PubMed.23058051.s13.e2" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e1" e2="DDI-PubMed.23058051.s13.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s13.e1" e2="DDI-PubMed.23058051.s13.e2" /></sentence><sentence text="" /><sentence text="Multi-dose administration of CLZ influences the pharmacokinetics and lipid-lowering properties of ATV"><entity charOffset="98-100" id="DDI-PubMed.23058051.s15.e0" text="ATV" /><entity charOffset="29-31" id="DDI-PubMed.23058051.s15.e1" text="CLZ" /><pair ddi="false" e1="DDI-PubMed.23058051.s15.e1" e2="DDI-PubMed.23058051.s15.e1" /><pair ddi="false" e1="DDI-PubMed.23058051.s15.e1" e2="DDI-PubMed.23058051.s15.e0" /></sentence><sentence text=" Collectively, an apparent interaction between selected drugs was evident" /><sentence text="" /></document>